# A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

> **NCT05862272** · PHASE3 · RECRUITING · sponsor: **Sumitomo Pharma Switzerland GmbH** · enrollment: 1000 (estimated)

## Conditions studied

- Uterine Fibroids
- Endometriosis

## Interventions

- **DRUG:** Relugolix Combination Tablet

## Key facts

- **NCT ID:** NCT05862272
- **Lead sponsor:** Sumitomo Pharma Switzerland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-14
- **Primary completion:** 2029-07
- **Final completion:** 2030-09
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862272, "A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05862272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*